NEW YORK (360Dx) – NeoGenomics on Thursday priced its previously announced public offering of 9.8 million shares of its common stock at $12.75 per share.

Gross proceed from the offering are expected to be approximately $125 million.

NeoGenomics has granted the underwriters a 30-day option to purchase up to 1.47 million additional shares of common stock at the public offering price, less underwriting discounts and commissions.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.